Bruce A. Feinberg, DO: Payers are caught in this limbo area of thinking about population health but being responsible at the patient level—which is your member, your crowd.
Ira Klein, MD, MBA, FACP: Yes.
Bruce A. Feinberg, DO: So how do you balance the 2 when you start to think about value and cost?
Ira Klein, MD, MBA, FACP: When I was on the payer side, we knew all of the rules regarding our various patient populations—commercial, who was fully insured; commercial, who was self-insured by [their] employer; and Medicare and Medicaid, and the rules of the government. We knew what was going on in those worlds and how we could try to pull levers to get more value for the care that we were providing, both in the population health base—for example, cardiovascular disease—and the high-cost, low-incidence diseases like cancer. In the commercial population, about 6 per 1000; Medicare maybe about 4 per 1000. And that leads to different strategies.
For population-based care, you can really implement value-based insurance design because the treatments are not expensive and you can remove some of those barriers without hurting anyone’s bottom line. And you can impact a lot of people who get it. It’s not a difficult equation to say, “I’ve had a heart attack. Now my ACE inhibitor and my beta-blocker are free.” Okay, more people are going to take ACE inhibitors and beta-blockers. I totally get that.
With the high-cost, low-incidence diseases is where we struggle. Because 5% of the population typically incurs 50% of the cost, the solutions have to be more personalized. At the same time, as Mike pointed out earlier, the decision maker is often not the patient. Then, as Alan said, it’s often the system. The reason being, the disease is so complicated that you often need to have the decision making made primarily by the provider or the provider group.
That leads you into the types of programs, like oncology medical homes, where you say that the patient’s really not going to be able to pick one of those 16 NCCN [National Comprehensive Cancer Network] regimens for a HER2—negative, node-positive, breast cancer. But, if I have a provider practice that signed a contract that says they’re going to use a narrowed portion of evidence-based medicine, then I kind of delegate that value to the practice. All I have to do is create an insurance design that creates a tiered network so that more patients will go there. And then I’ve tried to solve that by doing sort of a network model and delegating responsibility, and maybe some upwards and downwards risk to the provider group.
That’s how I’ve looked at it on the payer side. On the pharmaceutical side, it gets a little more complicated because “nobody pays retail.” So what’s being touted out there as cost is not actually the real cost. And when I think about the hierarchy of what I would want to eliminate to create more efficiency in the system, I’m not so sure I’d want to take a swing at the innovators first because there’s so much grit in the machine that there’s a lot of other things we can do to lower cost.
We didn’t talk about that political third rail. That’s a little less electric, but still is what we are doing with medical futility and care that’s given at the end of life. We haven’t really talked about why there are such low enrollments in clinical trials. And we haven’t talked about why people are hogging their data and locking it up in safes and not allowing innovation to move quicker. So I would rather take swings at those elements of the system that need to be fixed than something that involves a price that’s not actually the price.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More